Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account?-Reference-Cited by-同舟云学术

Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account?

Published:2024-01-12 Issue:2 Volume:17 Page:119-130
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Hermida Ramón C¹²³^ORCID,Smolensky Michael H³⁴^ORCID,Mojón Artemio¹²^ORCID,Fernández José R¹²^ORCID

Affiliation:

1. Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Telecommunication Technologies (atlanTTic), Universidade de Vigo, Vigo, Spain

2. Bioengineering & Chronobiology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain

3. Department of Biomedical Engineering, Cockrell School of Engineering, The University of Texas at Austin, Austin, TX, USA

4. Department of Internal Medicine, McGovern School of Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA

Funder

No funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2024.2304015

Reference65 articles.

1. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

2. National Institute for Health and Clinical Excellence. Hypertension in adults: diagnosis and management. NICE Guideline 136: Methods Evidence And Recommendations. National Clinical Guidelines Centre London (UK). 2019 [cited 2023 Jul 28]. Available from: https://www.nice.org.uk/guidance/ng136

3. 2020 International Society of Hypertension Global Hypertension Practice Guidelines

4. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension